Beximco Pharmaceuticals Limited

BXPHARMA

BD0453BXPH04

Pharmaceuticals

End-of-day quote Dhaka S.E. Other stock markets 06:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
117.7 ^BDT	-1.51%		-1.59%	-19.49%

Mar. 04	Beximco names Iqbal Ahmed as managing director	AN
Jan. 30	Beximco Pharmaceuticals to strengthen portfolio as interim profit up	AN

Beximco Pharmaceuticals Limited Recommends Dividend for the Year Ended on June 30, 2021

October 24, 2021 at 11:07 am EDT

Beximco Pharmaceuticals Limited Board of Directors has recommended 35% cash dividend for the year ended on June 30, 2021.

Latest news about Beximco Pharmaceuticals Limited

Beximco names Iqbal Ahmed as managing director	Mar. 04	AN
Beximco Pharmaceuticals to strengthen portfolio as interim profit up	Jan. 30	AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 30, 2023	Jan. 30	CI
Beximco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Jan. 29	CI
Beximco MD steps down to join Bangladeshi cabinet	Jan. 11	AN
Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Member of the Board	Jan. 11	CI
Beximco Pharmaceuticals Limited Announces Stepping Down of Mr. Nazmul Hassan as Managing Director	Jan. 11	CI
Beximco Pharmaceuticals Posts Higher Fiscal Q1 Profit, Revenue	Nov. 06	MT
Beximco Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 06	CI
Beximco boosts revenue in local currency but profit falls	Nov. 01	AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	Nov. 01	CI
Beximco Pharmaceuticals Limited Proposes Dividend for the Year Ended June 30, 2023	23-10-20	CI
Beximco working to fix deficiencies at manufacturing plant	23-09-11	AN
Beximco Pharmaceuticals to Tackle Ophthalmic Manufacturing Unit Deficiencies After Malta Medicines Authority Audit	23-09-11	MT
EARNINGS UPDATES: HC Slingsby profit falls, East Imperial loss narrows	23-05-02	AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-01	CI
TRADING UPDATES: Ferro-Alloy eyes revenue to drop below market view	23-01-30	AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-01-30	CI
Beximco Pharmaceuticals Limited Announces Cash Dividend for the Year Ended June 30, 2022	23-01-19	CI
UK shareholder meetings calendar - next 7 days	22-12-15	AN
EARNINGS SUMMARY: Goodbody shifts away from Covid; Beximco profit down	22-11-11	AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-11	CI
IN BRIEF: Beximco Pharmaceuticals revenue up thanks to domestic sales	22-11-08	AN
Beximco Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-11-08	CI
UK earnings, trading statements calendar - next 7 days	22-11-01	AN

Chart Beximco Pharmaceuticals Limited

Duration

Period

More charts

Beximco Pharmaceuticals Ltd. is a manufacturer and exporter of medicines in Bangladesh. The Company is engaged in manufacturing and marketing of generic pharmaceuticals formulation products covering a range of therapeutic categories. It offers products in different dosage forms including solid, liquid, cream and ointment, suppositories, metered dose inhaler, dry powder inhaler, nasal spray, sterile, lyophilized injectable and large volume intravenous fluids. It also manufactures active pharmaceutical ingredients (APIs) and renders contract manufacturing services to other companies. It produces different presentations, and the portfolio encompasses all key therapeutic categories, including antibiotics, analgesics, anti-diabetic, respiratory, cardiovascular, central nervous system, dermatology, gastrointestinal and others. The Company's products include Atrizin, Nomos, Azithrocin, Ceftoril, Bemsivir, Viraflu, Viracin, Rilovir, Flurium, Nervalin, Seropam, Nightus, and others.

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Beximco Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

117.7 BDT

Average target price

153.5 BDT

Spread / Average Target

+30.42%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BEXIMCO PHARMACEUTICALS LIMITED	-19.49%	478M
ELI LILLY AND COMPANY	+24.60%	654B
NOVO NORDISK A/S	+24.08%	552B
JOHNSON & JOHNSON	-5.63%	356B
MERCK & CO., INC.	+15.37%	319B
ABBVIE INC.	+7.38%	295B
ASTRAZENECA PLC	+3.26%	211B
NOVARTIS AG	+0.78%	206B
ROCHE HOLDING AG	-9.16%	197B
PFIZER, INC.	-9.69%	147B

Other Pharmaceuticals